Tackling drug resistance
Project LeaderDr David Ascher
Location: Bio21 Institute, 30 Flemington Rd
Drug resistance is a persistent and worldwide problem that has emerged as a grave and significant threat to public health, reducing the effectiveness of therapies that treat bacteria, parasites, viruses, fungi and cancer. Examining how genetic variation associated with resistance to therapeutic treatments manifests at the molecular level and how it affects organism fitness is vital to the development of new therapeutics. Moreover, there is potential to use such molecular level insights to identify future variations more prone to leading to resistance and answer specific questions around the modes of resistance in individual infectious diseases.
Identifying drug resistance mutations
Within protein coding regions resistance can be confirmed through a number of mechanisms including modulation of the drug compound’s target or, as many infectious disease drugs are delivered as pro-drugs, modulation of the proteins that convert the pro-drug to its active form. Mutations resulting in changing the profile of compounds that can be transported by efflux pumps is another means by which resistance can be introduced. Alternative routes to resistance that do not involve protein coding mutations include: the protection of drug targets by post-translational modifications such as methylation; the presence and increased expression of proteins that bind to targets preventing drug interactions; or limiting the physical entry of the drug compound to the cell or increasing the efficiency of drug efflux through increasing the type or number of drug efflux pumps. The project has so far focused on analysing those mutations in protein coding regions.
The aim of this project is to develop computational tools for automatically analysing the molecular consequences of mutations linked with therapeutic resistance and to use this wide-ranging analysis to build a predictive model to identify future mutations that could lead to therapeutic failure. By generating a few broad rules, we have been able to identify resistance mutations in whole genome Tuberculosis sequences, chemotherapeutic and HIV inhibitor resistance mutations, and antibody escape mutations in HIV and influenza. Using this to predict and anticipate how and when resistance is likely to arise will allow implementation of better drug use management to prolong drug efficacy. This is being developed as part of a platform to rapidly identify drug resistance in the clinic, guiding public health policy and patient treatment.
Designing resistance resistant treatments
If we can identify likely resistance mutations before they arise, it could be used to guide drug and biotherapeutic development in order to avoid sites identified as likely resistance hot-spots. This could reduce and/or delay the incidence of resistance. The ultimate goal is to integrate this analysis along with our pharmacokinetic and toxicity predictions into an integrated system where all the parameters can be explored and optimised in real time to aid the development of resistance resistant therapies.
Dr David Ascher, Group Leader
Dr Douglas Pires
Carlos Rodrigues, PhD Student
Malancha Karmakar, PhD Student
Stephanie Portelli, PhD Student
Willy Cornelissen, Masters Student
Professor Sir Tom Blundell, University of Cambridge
Professor Taane Clark, London School of Hygiene & Tropical Medicine
Dr Nick Furnham, London School of Hygiene & Tropical Medicine
Dr Kat Holt, University of Melbourne
Associate Professor Justin Denholm, Doherty Institute
Dr Katerina Artavanis-Tsakonas, University of Cambridge
Professor Véronique Dartois, Public Health Research Institute Center
Professor Taís Nóbrega de Sousa, Fiocruz-Minas
Professor Alexandre Machado, Fiocruz Minas, Brazil
Professor Rubens Neto, Fiocruz Minas
Newton Fund/MRC: "Understanding Antimicrobial Resistance Mutations in Tuberculosis: Towards Personalised Treatment to Combat Multi‐drug Resistance."
Jack Brockhoff Foundation Grant: “Understanding the Molecular Mechanisms of Complex Mutations”.
This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.
- Phelan J, Coll F, McNerney R, Ascher DB, Pires DE, Furnham N, Coeck N, Hill-Cawthorne GA, Nair MB, Mallard K, Ramsay A, Campino S, Hibberd ML, Pain A, Rigouts L, Clark TG. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Medicine 2016; 14: 31.
- Pires DEV, Blundell TL, Ascher DB. mCSM-lig: quantifying the effects of mutations on protein-ligand affinity in genetic disease and the emergence of drug resistance. Scientific Reports 2016; 6: 29575.
- Pires DEV, Chen J, Blundell TL, Ascher DB. In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Scientific Reports 2016; 6: 19848.
- Silvino ACR, Costa GL, de Araujo FCF, Ascher DB, Pires DEV, Fontes CJF, Carvalho LH, de Brito CFA, de Sousa TN. Variation in human cytochrome P-450 drug-metabolism genes: a gateway to understand Plasmodium vivax relapses. PLOS One 2016; 11: e0160172.
- Ascher DB, Wielens J, Nero TL, Morton CJ, Parker MW. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Scientific Reports 2014; 4: 4765.
Faculty Research Themes
School Research Themes
For further information about this research, please contact the research group leader.